8. (Amended) The method of Claim 1, wherein the TNFR:Fc is administered concurrently with a therapy selected from the group consisting of phototherapy with ultraviolet light B, psoralen combined with ultraviolet light A, plasmapheresis and sunbathing.

11. (Amended) The method of Claim 1, wherein the TNFR:Fc is administered in a sustained-release form selected from the group consisting of TNFR:Fc that is encapsulated in a biocompatible polymer, TNFR:Fc that is admixed with a biocompatible polymer, and TNFR:Fc that is encased in a semi-permeable implant.

12. (Amended) A method of treating psoriasis in a pediatric human patient having psoriasis comprising administering to said patient a therapeutically effective amount of TNFR:Fc, wherein the TNFR:Fc is administered by subcutaneous injection one or more times per week at a dose of 0.4 mg/kg of patient body weight, up to a maximum of 25 mg per dose.

13. (Amended) A method of treating psoriasis in an adult human patient having psoriasis comprising administering by subcutaneous injection to said patient a dose of 25 mg of TNFR:Fc two times per week for one or more weeks or a dose of 50 mg of TNFR:Fc one time per week or two times per week for one or more weeks.

Please add the following new claims to the application:

-- 19. (New) A method according to claim 1, wherein the psoriasis is selected from the group consisting of plaque psoriasis, guttate psoriasis, inverse psoriasis, erythrodermic psoriasis, pustular psoriasis, scalp psoriasis and nail psoriasis.

20. A method according to claim 12, wherein the psoriasis is selected from the group consisting of plaque psoriasis, guttate psoriasis, inverse psoriasis, erythrodermic psoriasis, pustular psoriasis, scalp psoriasis and nail psoriasis.

21. A method according to claim 13, wherein the psoriasis is selected from the group consisting of plaque psoriasis, guttate psoriasis, inverse psoriasis, erythrodermic psoriasis, pustular psoriasis, scalp psoriasis and nail psoriasis.

22. A method of treating psoriasis comprising administering to a patient having psoriasis a therapeutically effective amount of a soluble TNFα receptor, wherein said soluble TNFα receptor is administered in an amount and for a time sufficient to induce an improvement over baseline in an indicator selected from the